Latest news

• GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug

  GSK and iTeos are also planning to launch combination studies of the mAb with PD-1 inhibitor Jemperli (dostarlimab) in 2022.

• GSK wins approval for anti-PD-1 antibody Jemperli in endometrial cancer

  The Food and Drug Administration (FDA) has approved Jemperli(dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, following an FDA-approved

• GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours

  GlaxoSmithKline’s (GSK) dostarlimab – an investigational PD-1 inhibitor – has demonstrated promising results in patients with heavily pre-treated solid cancer tumours. ... This data shows that dostarlimab may become an important new treatment

• GSK pays $50m upfront to tap Immatics’ cell therapy platform

  for multiple myeloma and dostarlimab for endometrial cancer.

• GSK boosts outlook thanks to strong respiratory and vaccine sales

  GSK also highlighted the success of its new oncology medicine Dostarlimab, which is used in the treatment of advanced or recurrent endometrial cancer.